tetano
Editor, Senior Moderator
Novavax, Inc. (NVAX: Quote), a clinical-stage biopharmaceutical company creating vaccines, Monday reported positive preclinical data for the company's virus-like particle or VLP vaccine candidate against A(H7N9) influenza. The study involved a lethal wild-type challenge mouse model against which the immunogenicity and efficacy of two doses of A(H7N9) VLP vaccine candidate were examined.
Three control groups included Novavax' non-homologous A(H7N3) VLP vaccine candidate, its A(H5N1) VLP vaccine candidate, and a placebo. All vaccine candidates were administered with or without Iscomatrix, a saponin-based adjuvant.
"...Additionally, the study showed complete cross-protection when the VLP vaccine was not a perfect match for the challenge virus. We believe the combined rapid manufacture, animal efficacy data and evidence of cross-protection substantiate the potential of the Novavax vaccine technology as applied to emerging pandemic strains. These animal data add to our confidence that the vaccine candidate will elicit protective immune responses in humans..." said Dr. Gregory Glenn, Novavax' Chief Medical Officer.
http://www.rttnews.com/2160367/nova...ype=qf&utm_source=google&utm_campaign=sitemap
Three control groups included Novavax' non-homologous A(H7N3) VLP vaccine candidate, its A(H5N1) VLP vaccine candidate, and a placebo. All vaccine candidates were administered with or without Iscomatrix, a saponin-based adjuvant.
"...Additionally, the study showed complete cross-protection when the VLP vaccine was not a perfect match for the challenge virus. We believe the combined rapid manufacture, animal efficacy data and evidence of cross-protection substantiate the potential of the Novavax vaccine technology as applied to emerging pandemic strains. These animal data add to our confidence that the vaccine candidate will elicit protective immune responses in humans..." said Dr. Gregory Glenn, Novavax' Chief Medical Officer.
http://www.rttnews.com/2160367/nova...ype=qf&utm_source=google&utm_campaign=sitemap